The share price of Rs 18 has gone up to Rs. 1300, 7.25 lakh return on investment of 10 thousand

 Wealth: The share price of Rs 18 has gone up to Rs. 1300, 7.25 lakh return on investment of 10 thousand

Pharma stock Orchid has also beaten Bitcoin in terms of returns

Shares of a bankrupt pharma company have risen more than 7,000 percent in the last four months. The stock still has an upper circuit. This is the case of the bankrupt company Orchid Pharma Limited. Orchid Pharma was bought by Dhanuka Lab under NCLT's resolution plan after it went bankrupt in fact. Since then, shares of Orchid Pharma have risen significantly.

ગુજરાતી માં ન્યૂઝ વાંચો 

Pharma stock Orchid has also beaten Bitcoin in terms of returns. Where Orchid Pharma shares have returned more than 7000 percent in the last 4 months. There has been a 203 percent return on Bitcoin.

Also read 😲😅🤣મિત્રો આજે  પુરુષ માંથી  મહિલા જેવો તમારા ચહેરો દેખાશે 

Orchid Pharma Company was re-listed on November 3, 2020.

Orchid Pharma was re-listed on the stock exchange on November 3, 2020. The company's share price has never declined since then. Since the day of the re-listing, the company's stocks have been on a daily circuit. The stock hit a 5 per cent upper circuit on Wednesday, March 10 and closed at Rs 1,307.55 on the NSE.

Also read 💥ધોરણ 8 પાસ પર નવી ભરતી

At the time of re-listing, the share price was Rs. Was 18

When Orchid Pharma Company was re-listed on November 3, 2020, the share price rose to Rs 18, which rose to Rs 10 on March 10, 2021. 1,307.55. Thus, if investors had invested Rs 10,000 in just 128 days, they would have got a return of Rs 7.25 lakh.

Dhanuka Lab has a 98.04 per cent stake in Orchid Pharma.

Market cap rises to over Rs 5,000 crore

The company had a revenue of Rs 102.63 crore in December this year and a loss of Rs 45.33 crore. The company had a revenue of Rs 505.45 crore in March 2020 and a net loss of Rs 149.84 crore. The Chennai-based pharma company has grown its market cap to over Rs 5,000 crore.

Dhanuka Lab has a 98.04 per cent stake in Orchid Pharma. Apart from this, other financial institutions have a stake of 1.19 per cent, while retail investors have only 0.5 per cent stake in the company. This shortage of the company's stocks has led to a surge in share prices.